MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Home・Akcijų sąrašas・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

41.42 2.7

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

39.64

Max

41.98

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-6.2M -91M
Pelno marža	-867.293
Darbuotojai	316
EBITDA	4M -90M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+31.19% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-26

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-44M 3.2B
Ankstesnė atidarymo kaina	38.72
Ankstesnė uždarymo kaina	41.42

Naujienos nuotaikos

By Acuity

50%

151 / 361 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

34.81 / 38.24 Palaikymas ir pasipriešinimas

Xenon Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-14 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

2026-01-15 00:00; UTC

Uždarbis

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

2026-01-14 23:47; UTC

Rinkos pokalbiai

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

2026-01-14 23:44; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

2026-01-14 23:39; UTC

Rinkos pokalbiai

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

2026-01-14 23:32; UTC

Rinkos pokalbiai

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

2026-01-14 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

2026-01-14 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

2026-01-14 22:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-14 22:17; UTC

Rinkos pokalbiai

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

2026-01-14 22:09; UTC

Uždarbis

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

2026-01-14 22:08; UTC

Uždarbis

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

2026-01-14 22:08; UTC

Uždarbis

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

2026-01-14 21:53; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

2026-01-14 21:53; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

2026-01-14 21:52; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Announces Positive Profit Alert for 2025

2026-01-14 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup Acting as Financial Advisor to WuXi XDC

2026-01-14 21:51; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC: Aims to Keep Listing Status of BioDlink

2026-01-14 21:51; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

2026-01-14 21:50; UTC

Rinkos pokalbiai

Uždarbis

Financial Services Roundup: Market Talk

2026-01-14 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-14 21:49; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC: BioDlink Offer to Cost HK$2.79B

2026-01-14 21:48; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

2026-01-14 21:48; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Makes Cash Offer for BioDlink International

2026-01-14 21:13; UTC

Rinkos pokalbiai

Oil Retreats Late After Trump Comments on Iran -- Market Talk

2026-01-14 20:30; UTC

Rinkos pokalbiai

Uždarbis

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

2026-01-14 20:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

2026-01-14 20:08; UTC

Rinkos pokalbiai

Oil Futures Extend Rally on Iran Tensions -- Market Talk

2026-01-14 19:33; UTC

Rinkos pokalbiai

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

2026-01-14 19:06; UTC

Rinkos pokalbiai

Uždarbis

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Akcijų palyginimas

Kainos pokytis

Xenon Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

31.19% į viršų

12 mėnesių prognozė

Vidutinis 54.09 USD 31.19%

Aukščiausias 62 USD

Žemiausias 44 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Xenon Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių Xenon Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

34.81 / 38.24Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

151 / 361 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.